Tonix Pharmaceuticals Reports 37% Quarterly Sales Growth for TONMYA and Outlines Phase II Clinical Trial Timeline
Tonix Pharmaceuticals Holding Corp. (TNXP) reported a significant increase in revenue for its product TONMYA, with third-quarter net sales reaching approximately $15 million. This represents a 37% increase compared to the previous quarter, driven by expanded market performance. Looking ahead, the company announced plans to initiate the TRAIL Phase II clinical trial for TNX-4800 in the first quarter of 2027. The study aims to enroll approximately 3,300 participants. Additionally, Tonix noted that patents protecting TONMYA are secured through 2034, providing long-term market exclusivity.
Tickers: $TNXP